Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 216

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Linking Metabolism and Immunology: Diabetic Nephropathy Is an Inflammatory Disease

Tuttle, Katherine R. · 2005 · Journal of the American Society of Nephrology

Abstract

Diabetic nephropathy is one of the most important concerns in nephrology, as well as in medicine at large. Rapidly increasing rates of diabetes throughout the developed world represent an emerging epidemic with profound consequences. This epidemic is likely to drive previously unforeseen rates of vascular target organ complications. As survival from acute cardiovascular complications continues to improve, management of chronic complications such as kidney disease assume ever-larger roles. Diabetes is the leading cause of end-stage renal disease in the United States, accounting for approximately 45% of incident cases and 55% of prevalent cases in the present decade (1,2). End-stage renal disease in diabetes, particularly type 2, has been described as a medical catastrophe of worldwide dimensions (3). So what can be done to reduce the burden of diabetic nephropathy? Available therapies shown to prevent or slow progression should be broadly applied. These therapies include strict glycemic control and treatment of hypertension with inhibitors of the renin-angiotensin system (4–10). However, in recent clinical trials in which care was presumably optimized, renoprotecion was far from complete. And, in reality, controlling hyperglycemia and hypertension in usual care settings is often more challenging than in clinical trials. Hence, even more effective therapies that interrupt mechanisms of kidney damage induced by hyperglycemia and/or hypertension are urgently needed. The bench-to-bedside paradigm of translational research is that two-way street where the clinic and the laboratory meet. For clinicians and patients, this is an opportunity to obtain more effective therapies. For scientists, discovery and technology can be applied to a meaningful clinical problem. Two elegant papers in this issue of the journal illustrate the hope of translational research (11,12). The paper by Kelly and colleagues utilized a model of diabetes and hypertension produced by administration of streptozotocin to a rat transgenic for the renin gene (11). Groups of diabetic and control rats were treated, or not, with an inhibitor of protein kinase C-β (PKC-β), ruboxistaurin. Although glomerular pathology has been well characterized in this model, the current paper emphasizes the importance of tubulointerstitial injury (11,13). Macrophage accumulation and injury at this site correlate closely with loss of kidney function in humans and animals with a range of kidney diseases, including diabetic nephropathy (14,15). This model of diabetes and hypertension demonstrated numerous macrophages in the interstitium of untreated rats, along with widespread and intense tubular staining for osteopontin, a protein known to recruit macrophages (11). Pro-fibrotic injury markers (interstitial collagen, tubular TGF-β, and a marker of its activity, phosphorylated Smad2) were also increased. Despite persistent hyperglycemia and hypertension, albuminuria was reduced, and renal function was preserved in rats treated with ruboxistaurin. Moreover, tubulointerstitial macrophage accumulation, osteopontin expression, and pro-fibrotic injury markers were returned to control levels by this treatment. These observations have important translational implications. First, ruboxistaurin has already moved into clinical trials for diabetic nephropathy, as well as for other microvascular complications (16). The data reported by Kelly and colleagues provide further scientific rationale and biologic plausibility for how this drug may ameliorate kidney disease even when hyperglycemia and hypertension are not well controlled, a situation all too common in the clinical realm (11). Second, on the scientific side, mechanisms of PKC-β activation and its actions provide insight into how a classic metabolic disease, diabetes, is linked to an immunological signature, inflammation. PKC is composed of at least 12 isoforms which signal a number of cellular responses, including oxidative stress, activation and/or expression of inflammatory mediators, cellular proliferation, and tissue fibrosis (16). Various PKC isoforms, particularly PKC-β, are activated in diabetes. Hyperglycemia, acting through generation of cellular diacylglycerol, is a predominant PKC activator, but advanced glycation end products (AGE) and other metabolic products may also participate in activation (16). Intracellular adhesion molecule (ICAM)-1 is expressed on the surface of a number of cell types in response to PKC activation (17–19). ICAM-1 promotes inflammation by enhancing leukocyte infiltration and adherence. In a complementary paper, Chow and colleagues illustrate yet another dimension of the link between diabetes and inflammation by examining the role of ICAM-1 in glomerular and tubulointerstitial disease in db/db mice (12). These mice spontaneously develop hallmarks of type 2 diabetes, including hyperglycemia, hyperinsulinemia, and obesity. Their kidney disease is manifest by albuminuria, decreased GFR, glomeru

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2005040393

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 216

Metadata

Authors
Tuttle, K. R.
Venue
Journal of the American Society of Nephrology
Published
2005-06
Volume
16
Issue
6
Pages
1537-1538
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2146280915
Cited by
216
References
3
FWCI
4.21
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Linking Metabolism and Immunology: Diabetic Nephropathy Is an Inflammatory Disease. https://app.cochat.ai/papers/10.1681/asn.2005040393
The paper
Tuttle, K. R. (2005). Linking Metabolism and Immunology: Diabetic Nephropathy Is an Inflammatory Disease. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2005040393

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.